The Ministry of Health finances for the first time, since November 1, a vaginal contraceptive ring: a combined hormonal contraceptive from which some 37,000 women will benefit.
Specifically, the National Health System (SNS) includes in its service portfolio the ring with the active substances ethinyl estradiol (3,474 mg) and etonogestrel (11 mg), according to Health.
Currently, public health already finances other contraceptives authorized in Spain and thus are included in the pharmaceutical portfolio several contraceptives that are administered orally, combined hormonal and progestogen-based.
Different reversible long-term contraceptives, known as LARC, are also funded , such as three types of intrauterine devices (IUDs), injectable medroxyprogesterone and etonogestrel implants.
The SNS finances a total of fourteen presentations of state-of-the-art contraceptives, also called fourth-generation because they have been developed to achieve, in addition to contraceptive efficacy, beneficial non-contraceptive effects. Its main characteristic is antiandrogenicity.
According to the criteria of The Trust Project
Know more- Science and Health
- Health
HealthThe Patient Advocate urges the Prosecutor's Office to investigate listeria in Aldi pancakes
Health National Parks reduce the global cost of mental health by more than five billion euros a year
HealthThe rise of the deadly black vaping market in the US